Literature DB >> 20304099

Level of hepatitis B virus DNA in inactive carriers with persistently normal levels of alanine aminotransferase.

Chia-Ming Chu1, Yi-Cheng Chen, Dar-In Tai, Yun-Fan Liaw.   

Abstract

BACKGROUND & AIMS: Little is known about the level of hepatitis B virus (HBV) DNA in individuals with chronic, inactive HBV infections. Patients who test positive for the antibody to hepatitis B e antigen (anti-HBe) and have normal levels of alanine aminotransferase for more than 10 years have a low risk of HBV reactivation and are considered to be inactive carriers. We investigated HBV DNA levels in inactive carriers and identified factors that correlated with this state among anti-HBe-positive carriers with HBV DNA levels of 10(4) copies/mL or greater (5.26 copies/mL = 1 IU/mL).
METHODS: HBV DNA levels were assayed in 250 inactive carriers with persistently normal alanine aminotransferase levels for more than 10 years. Clinical and virologic features were compared between inactive carriers (with HBV DNA levels > or =10(4) copies/mL) and age-matched patients with HBe antigen-negative chronic hepatitis (controls, n = 90).
RESULTS: The median level of HBV DNA among inactive carriers was 3.70 log(10) copies/mL (range, undetectable to 5.98 log(10) copies/mL). Ninety (36%) had levels of 10(4) copies/mL or greater. Compared with control patients, significant differences of inactive carriers included sex (more female patients), lower HBV DNA levels, and lower prevalence of genotype C virus and the basal core promoter mutation T1762/A1764. The prevalence of the precore mutation A1896 was similar between groups. Multiple logistic regression analyses identified male sex, HBV DNA levels greater than 10(5) copies/mL, and the basal core promoter mutation as independent factors that correlated with active disease.
CONCLUSIONS: Nearly 40% of inactive carriers had HBV DNA levels of 10(4) copies/mL or greater. Female sex, HBV DNA levels of 10(4) to 10(5) copies/mL, and wild-type basal core promoter correlated with inactive carrier state. Copyright 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20304099     DOI: 10.1016/j.cgh.2010.03.006

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  10 in total

1.  Viral load, genotypes, and mutants in hepatitis B virus-related hepatocellular carcinoma: special emphasis on patients with early hepatocellular carcinoma.

Authors:  Chia-Ming Chu; Chen-Chun Lin; Shi-Ming Lin; Deng-Yn Lin; Yun-Fan Liaw
Journal:  Dig Dis Sci       Date:  2011-08-12       Impact factor: 3.199

Review 2.  Immune therapy for hepatitis B.

Authors:  Sheikh Mohammad Fazle Akbar; Mamun Al-Mahtab; Md Sakilur Islam Khan; Ruksana Raihan; Ananta Shrestha
Journal:  Ann Transl Med       Date:  2016-09

3.  Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update.

Authors:  Yun-Fan Liaw; Jia-Horng Kao; Teerha Piratvisuth; Henry Lik Yuen Chan; Rong-Nan Chien; Chun-Jen Liu; Ed Gane; Stephen Locarnini; Seng-Gee Lim; Kwang-Hyub Han; Deepak Amarapurkar; Graham Cooksley; Wasim Jafri; Rosmawati Mohamed; Jin-Lin Hou; Wan-Long Chuang; Laurentius A Lesmana; Jose D Sollano; Dong-Jin Suh; Masao Omata
Journal:  Hepatol Int       Date:  2012-05-17       Impact factor: 6.047

Review 4.  Clinical utility of HBV surface antigen quantification in HBV e antigen-negative chronic HBV infection.

Authors:  Yun-Fan Liaw
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-09-02       Impact factor: 46.802

5.  Effects of sex and generation on hepatitis B viral load in families with hepatocellular carcinoma.

Authors:  Ai-Ru Hsieh; Cathy Sj Fann; Chau-Ting Yeh; Hung-Chun Lin; Shy-Yi Wan; Yi-Cheng Chen; Chia-Lin Hsu; Jennifer Tai; Shi-Ming Lin; Dar-In Tai
Journal:  World J Gastroenterol       Date:  2017-02-07       Impact factor: 5.742

6.  Performance verification and comparison of TianLong automatic hypersensitive hepatitis B virus DNA quantification system with Roche CAP/CTM system.

Authors:  Ming Li; Lin Chen; Li-Ming Liu; Yong-Li Li; Bo-An Li; Bo Li; Yuan-Li Mao; Li-Fang Xia; Tong Wang; Ya-Nan Liu; Zheng Li; Tong-Sheng Guo
Journal:  World J Gastroenterol       Date:  2017-10-07       Impact factor: 5.742

7.  Gamma-glutamyl Transpeptidase to Platelet Ratio Predicts Liver Injury in Hepatitis B e Antigen-negative Chronic Hepatitis B Patients With Normal Alanine Aminotransferase.

Authors:  Xiang-An Zhao; Jian Wang; Jie Wei; Jiacheng Liu; Guangmei Chen; Li Wang; Guiyang Wang; Juan Xia; Weihua Wu; Shengxia Yin; Xin Tong; Xiaomin Yan; Weimao Ding; Xiaoxing Xiang; Rui Huang; Chao Wu
Journal:  J Clin Transl Hepatol       Date:  2021-07-14

8.  Basal core promoter mutation is associated with progression to cirrhosis rather than hepatocellular carcinoma in chronic hepatitis B virus infection.

Authors:  C-M Chu; C-C Lin; Y-C Chen; W-J Jeng; S-M Lin; Y-F Liaw
Journal:  Br J Cancer       Date:  2012-10-18       Impact factor: 7.640

9.  Patients with Coexistence of Circulating Hepatitis B Surface Antigen and Its Antibody May Have a Strong Predisposition to Virus Reactivation During Immunosuppressive Therapy: A Hypothesis.

Authors:  Yu-Lan Chen; Ying-Qian Mo; Dong-Hui Zheng; Jian-Da Ma; Jun Jing; Lie Dai
Journal:  Med Sci Monit       Date:  2017-12-17

Review 10.  Nature of Host Immunity during Hepatitis B Virus Infection and designing Immune Therapy.

Authors:  Sheikh Mf Akbar; Mamun Al-Mahtab; Sakirul I Khan
Journal:  Euroasian J Hepatogastroenterol       Date:  2018-05-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.